Milestone Pharmaceuticals Inc. 8-K

What Happened

• Milestone Pharmaceuticals Inc. (MIST) filed an 8-K reporting results of its June 10, 2026 annual meeting. Shareholders approved an amendment to the Company’s 2019 Equity Incentive Plan to increase the number of ordinary shares authorized for issuance by 6,800,000 shares. The amended 2019 EIP is attached as Exhibit 10.1 to the filing.
• All eight director nominees were elected to the Board to hold office until the 2027 annual meeting. Shareholders also ratified PricewaterhouseCoopers LLP as auditor and cast a non-binding advisory vote on executive compensation.

Key Details

• Meeting date: June 10, 2026.
• Equity plan amendment: Approved to add 6,800,000 ordinary shares to the 2019 Equity Incentive Plan (see Exhibit 10.1).
  • Vote on 2019 EIP amendment: For 19,262,773; Against 5,479,043; Abstentions 2,617,059; Broker Non-Votes 48,581,158.
• Director elections (votes For / Withheld / Broker Non-Votes):
  • Joseph Oliveto: 23,968,376 / 3,390,500 / 48,581,157
  • Stuart M. Duty: 24,188,870 / 3,170,005 / 48,581,158
  • Seth H.Z. Fischer: 24,199,513 / 3,159,363 / 48,581,157
  • Lisa M. Giles: 24,212,031 / 3,146,845 / 48,581,157
  • Joseph C. Papa: 23,437,235 / 3,921,639 / 48,581,159
  • Andrew R. Saik: 24,111,218 / 3,247,657 / 48,581,158
  • Michael Tomsicek: 24,205,006 / 3,153,870 / 48,581,157
  • Robert J. Wills: 23,506,189 / 3,852,686 / 48,581,158
• Auditor ratification: PricewaterhouseCoopers LLP ratified as auditor.
  • Auditor vote: For 75,025,285; Against 249,836; Abstentions 664,912.
• Advisory (say-on-pay) vote: For 19,665,705; Against 6,990,920; Abstentions 702,247; Broker Non-Votes 48,581,161.

Why It Matters

• The approved amendment authorizes up to 6.8 million additional ordinary shares for issuance under the 2019 Equity Incentive Plan, enabling the company to grant equity awards for hiring, retention or incentives; if issued and vested, such awards will increase shares outstanding and may dilute existing shareholders.
• Ratification of the auditor ensures continuity in financial reporting oversight. The advisory vote on executive compensation was non-binding but shows the level of shareholder support for pay practices.
• Investors tracking dilution, executive pay sentiment or board composition should note the vote totals and the additional share authorization.